1 / 25

Goal:

Goal:. design. design. perospirone. 11C-FLB457. Why?. perospirone. 11C-FLB457. perospirone. 11C-FLB457. 11C-FLB457. perospirone. perospirone. 11C-FLB457. perospirone. 11C-FLB457. From Vernaleken et al…. In the Arakawa paper, where does the baseline (aka ‘control’) data come from?.

tdixon
Download Presentation

Goal:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Goal:

  2. design

  3. design perospirone 11C-FLB457 Why? perospirone 11C-FLB457 perospirone 11C-FLB457 11C-FLB457 perospirone perospirone 11C-FLB457 perospirone 11C-FLB457

  4. From Vernaleken et al… In the Arakawa paper, where does the baseline (aka ‘control’) data come from?

  5. From Vernaleken et al… DOES THIS MAKE SENSE?

  6. Design of healthy control study: This is a “single dose” study – why? As opposed to _______________?

  7. Design of healthy control study: 11C-raclopride Baseline perospirone 11C-raclopride 11C-raclopride 11C-raclopride This is a “single dose” study – why? As opposed to _______________?

  8. Healthy controls Why use 11C-raclopride here?

  9. Goal:

  10. design ‘short’ ‘long’

  11. design ‘short’ ‘long’ Ziprasodone 11C-fallypride Ziprasodone 11C-fallypride Ziprasodone 11C-fallypride 11C-fallypride Ziprasodone 11C-fallypride Ziprasodone 11C-fallypride Ziprasodone

  12. Again, where do the baseline data come from in this design? Can they do that? Problems?

  13. Allows for different levels of occupancy for different regions. Multiple doses of drug, I guess

  14. Lower EC50 for putamen compared to other (extrastriatal) regions means lower receptor occupancy by the drug (ziprasodone) for a given plasma concentration.

  15. Suggests that there is a discrepancy between single dose measurements of occupancy and ‘steady state dosing’ But what else could it be? Perhaps: Chronic treatment with Zipras leads to upregulation of receptors and lower occup levels…

  16. 001

  17. Healthy controls Why use 11C-raclopride here? Dosimetry? Repeated scans on same day? Displaceability in striatum? DIFFERENT STUDIES DONE AT DIFFERENT CENTERS

  18. Goal:

  19. But to do microdose study, the drug company would have to give the chemical formula to the university PET center… so they could label it.

More Related